Previous 10 | Next 10 |
2023-09-28 11:25:05 ET With a stock down nearly 50% over the last 52 weeks, investors in Guardant Health (NASDAQ: GH) haven't had a lot to cheer about this year. The last couple of days, however, may be changing that. This morning, an endorsement from investment bank Bernstein s...
2023-09-27 15:41:37 ET More on Guardant Health Guardant Health, Inc. (GH) Q2 2023 Earnings Call Transcript Guardant Health, Inc. 2023 Q2 - Results - Earnings Call Presentation Guardant Health: A Growth Company Expanding Its Product Line Quickly Guardant Healt...
2023-09-26 10:50:17 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an ...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / September 18, 2023 / Gamehost Inc. (‘Gamehost', the ‘Company') (TSX:GH) Gamehost has declared a cash dividend for the month of September 2023 of $0.03 (CDN) per ...
First blood-only liquid biopsy test for minimal residual disease now covered for patients with stage II or III colorectal cancer Test used after surgery or curative treatment to inform physician decisions about adjuvant therapy and to monitor for disease progression, recurrence or relapse...
Blood test provides simple way for oncologists to test patients with advanced NSCLC for genomic alterations that drive selection of HER2-targeted therapy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Japanese Ministry of Health, Labour a...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in pa...
2023-09-01 15:00:48 ET More on the markets My Current View Of The S&P 500 Index: September 2023 Edition The 'Big Short' Ignores Buffett And Bets Big On A Selloff: SPY Implications Is The Market Ignoring Signs Of An Imminent Debt Crisis? For further detail...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 21 st Annual Global Healthcare Conference in New York, New York. Guardant Health’s management is scheduled to participate in a fires...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced the company will be hosting an Investor Day on September 7, 2023, in New York City, NY s...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...